Sio Gene Therapies Inc - ESG Rating & Company Profile powered by AI
The Disclosure score includes seventeen UN SDGs including: 'Affordable & Clean Energy', 'Reduced Inequalities' and 'Peace, Justice & Strong Institutions'. The page contains a free ESG report for Sio Gene Therapies Inc. Full Sustainability analysis of Sio Gene Therapies Inc can be reached by logging in.
Sio Gene Therapies Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.3; made up of an environmental score of 2.7, social score of 3.2 and governance score of 4.0.
3.3
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1234 | Quanterix Corp | 3.4 | Medium |
1234 | X4 Pharmaceuticals Inc | 3.4 | Medium |
1253 | Sio Gene Therapies Inc | 3.3 | Medium |
1253 | Calithera Biosciences Inc | 3.3 | Medium |
1253 | Cara Therapeutics Inc | 3.3 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does Sio Gene Therapies Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Sio Gene Therapies Inc report the average age of the workforce?
Sign up for free to unlockDoes Sio Gene Therapies Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Sio Gene Therapies Inc offer flexible work?
Sign up for free to unlockDoes Sio Gene Therapies Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Sio Gene Therapies Inc conduct supply chain audits?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Sio Gene Therapies Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose water use targets?
Sign up for free to unlockDoes Sio Gene Therapies Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Sio Gene Therapies Inc have a product recall in the last two years?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Sio Gene Therapies Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Sio Gene Therapies Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose parental leave metrics?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Sio Gene Therapies Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Sio Gene Therapies Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Sio Gene Therapies Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose its waste policy?
Sign up for free to unlockDoes Sio Gene Therapies Inc report according to TCFD requirements?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose energy use targets?
Sign up for free to unlockDoes Sio Gene Therapies Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Sio Gene Therapies Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Sio Gene Therapies Inc
These potential risks are based on the size, segment and geographies of the company.
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.